Earkart544549Regulatory approval
US FDA establishment registration and device listing completed for hearing aid products
Earkart Ltd says it has completed US FDA Establishment Registration and Device Listing for its hearing aid products.
By ScoutQuest · · 1 min read
- FDA registration completed
- US FDA Establishment Registration and Device Listing for its hearing aid products
- Product groupings
- five heads, covering prescription and over-the-counter models
- Stated market focus
- efforts to explore business opportunities in the United States market
What was announced
- Earkart Ltd has completed US FDA Establishment Registration and Device Listing for its hearing aid products.
- The company calls this a significant milestone in its growth journey and a marker of its focus on product quality, regulatory compliance and global expansion.
The products named
- Hearing Aid, Air-Conduction, Prescription: Fame (FA221), Fame 2T (FA224), Fame P (FA222), Fame SP (FA223), Fort UP (FA225).
- Hearing Aid, Air-Conduction, Over-the-Counter: PACE (PA16531), Radius 12 (RA12331), Radius 16 (RA16331), Radius 8 (RA8331), SPIN (SP16431).
- Hearing Aid, Air-Conduction with Wireless Technology, Over-the-Counter: CURV (CU16631), EQFY (EQB2302).
- Hearing Aid, Air-Conduction with Wireless Technology, Prescription: CORE (CO16731).
- Hearing Aid, Master: TINY (TY16831).
What this step involves
- Establishment Registration and Device Listing are the US FDA record-keeping steps through which a manufacturer's facility and its devices are placed on file with the US regulator.
- The company states that completing this process strengthens its international regulatory credentials and supports its strategic efforts to explore business opportunities in the United States market.
How to read the announcement
- The update is about a completed regulatory step for the named hearing aid models. The company's own framing is about quality, compliance and a wider international footprint.
- It is a business and regulatory update rather than a financial disclosure, so the emphasis is on market access and credentials rather than on any commercial outcome.
What the company says it will do next
- It states it remains committed to innovation, operational excellence and adherence to applicable global regulatory requirements as it pursues its growth objectives.
- It says it looks to build on this milestone to strengthen its presence in the global hearing healthcare industry.
Also from Earkart
Earkart H1 FY27 investor presentation: revenue up 39.42%, EBITDA down 41.94%, PAT down 61.27%
21 Nov 2026
Earkart schedules H1 FY27 earnings call for November 26, 2026 at 4:00 PM IST
21 Nov 2026
Board approves H1 results and incorporation of a wholly-owned subsidiary in Australia
5 Nov 2026
More numbers
- Product groupings listed in the updatefive
Source: BSE · 20 Nov 2026
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.